GlaxoSmithKline sale sparks rumour of share buyback programme
News of a fresh repurchase scheme could come on Thursday, when the drugmaker announces its full-year results.
Chief Executive Andrew Witty said in December that the time to resume buybacks was getting closer, but a big legal charge last month led investors to believe GSK would have to postpone.
Advertisement
Hide AdAdvertisement
Hide AdAnalysts said the Quest divestment may give GSK the confidence to commit to repurchases this year.
“The proceeds from the Quest sales should now allow the company to restart its repurchase programme,” said Jeff Holford, an analyst at Jefferies, who believes a buyback is imminent.
In a statement, GSK did not comment specifically on its buyback plans but said the Quest sale was designed to boost returns to shareholders.
“We have decided that now is a good time to take advantage of favourable market conditions, thereby releasing funds from one of our non-core assets,” said finance chief Julian Heslop.
GSK acquired the Quest stake as part payment for the sale of its clinical laboratories business in 1999.